28.9 C
Vientiane
Sunday, July 6, 2025
spot_img
Home Blog Page 304

Eternity Waterproofing Pte Ltd to Enhance Expertise with Thermal Imaging Certification


SINGAPORE – Media OutReach Newswire – 1 May 2025 – Eternity Waterproofing Pte Ltd, a leading provider of waterproofing services in Singapore, is proud to announce that its specialists will soon achieve the Level 1 Infrared Thermography Certification. This globally recognised certification, offered by the Institute of Infrared Thermography (IIRT) Singapore, empowers professionals to utilise advanced thermal imaging technology for precise water leak detection within buildings.

Thermal Imaging Detect Leaking
Thermal Imaging Detect Leaking

The certification underscores the company’s commitment to delivering superior service and ensuring optimal results for its clients. By integrating this cutting-edge technology, Eternity Waterproofing will enhance its ability to provide more effective waterproofing solutions, including roof waterproofing, spalling concrete repair, wall leakage repair, ceiling leakage repair, and a range of other related services.

A Game-Changing Approach to Leak Detection

The incorporation of thermal imaging technology revolutionises the way water leaks are detected. Unlike traditional methods that often involve invasive procedures, thermal imaging enables Eternity Waterproofing’s certified specialists to accurately pinpoint hidden leaks behind walls, ceilings, and floors. This non-invasive technique significantly reduces the risk of additional property damage, minimises the need for exploratory demolition, and accelerates the repair process.

“By integrating thermal imaging into our services, we can offer faster, more accurate diagnoses of water intrusion issues,” said Leo Zi Ming, Director. “This not only saves time and money for our clients but also delivers a more effective, long-term solution to water damage prevention.”

Investing in Technology and Expertise

To meet the rigorous standards of the Certification, Eternity Waterproofing has made significant investments in state-of-the-art infrared cameras and equipment. The company now employs high-resolution thermography cameras from renowned brands such as FLIR and HIKMICRO, which are specifically designed to detect even the slightest temperature variations caused by water intrusion.

Along with advanced cameras, Eternity Waterproofing has also adopted specialised software to interpret and document thermal images, providing more detailed reports and improving diagnostic accuracy. These reports, which can only be generated by licensed professionals, ensure compliance with industry standards and provide clients with reliable documentation for any necessary repairs or insurance claims.

Thermal imaging will be seamlessly integrated with other diagnostic technologies, including moisture meters and pressure testing systems, offering a comprehensive, multi-faceted approach to non-invasive leak detection.

Expanding Opportunities and Building Trust

This certification opens new opportunities for Eternity Waterproofing in key markets, including real estate inspections, insurance assessments, and commercial property maintenance. Certified thermal imaging specialists can offer preemptive leak detection services to property managers, builders, and insurers, ensuring that potential water-related issues are identified early on and prevented before they escalate into costly repairs.

Furthermore, the certification enhances Eternity Waterproofing’s industry credibility, assuring clients that they work with highly trained professionals using the latest technology. This strengthens customer trust, fosters long-term partnerships, and encourages increased referrals.

Hashtag: #thermalimagingcertification #thermalimaging #waterproofing #waterproofingcompany


The issuer is solely responsible for the content of this announcement.

About Eternity Waterproofing Pte Ltd

Founded in 2012, Eternity Waterproofing Pte Ltd has established itself as a with over 12 years of experience. The company specialises in waterproofing a variety of building systems, including pitched roof tiles, RC roofs, metal roofs, and external walls, ensuring that structures remain dry and free from water intrusion.

In addition to its core waterproofing offerings, Eternity Waterproofing offers effective repair solutions for common water leakage issues, such as inter-floor seepage, ceiling leaks, and basement wall leaks. The company also provides concrete and structural repair work, making it a comprehensive, one-stop solution for a wide range of water damage and prevention services. One of their key offerings is the advanced water seepage repair method, which efficiently addresses water penetration problems, ensuring long-lasting results and the protection of your property.

TECNO Launches Shot On CAMON Contest 2025, Empowering Snapshot Mastery with the CAMON 40 Series

HONG KONG, May 1, 2025 /PRNewswire/ — Today, TECNO, an AI-driven innovative technology brand, officially announced the launch of the Shot On CAMON Contest 2025. The annual photography contest now spotlights the groundbreaking FlashSnap function with three submission categories, and is once again inviting smartphone photography enthusiasts worldwide to capture and share life’s extraordinary moments using the award-winning TECNO CAMON 40 Series.

Running from May 1 to September 30, 2025, participants can enter by posting photos taken with the CAMON 40 Series on Instagram using the hashtags #ShotOnCAMON and #TECNOCAMON40Series. The Shot On CAMON Contest 2025 has a $10,000 Grand Prize and generous theme-based awards with more cash prizes, smartphones and even a trip to London up for grabs!

As TECNO’s flagship AI smartphone, the CAMON 40 Series harnesses TECNO AI to deliver a seamless experience. Its innovative One-Tap FlashSnap Mode combines a high-speed shutter with the BestMoment AI algorithm, allowing users to instantly capture clear and stable dynamic scenes. Even in fast-paced environments, users can effortlessly capture professional-grade photos without missing a single moment.

This year’s contest partners once again with Amateur Photographer, the world’s longest-running magazine, ensuring expert and credible judging. With a 78% global reach among enthusiasts, its technical authority and wide appeal are especially valuable in emerging markets. A panel of expert judges from both Amateur Photographer and TECNO’s imaging team will evaluate all entries based on instant capture ability, emotional intention, use of light and color, and composition and image quality.

“Last year’s winners earned a London trip, where we witnessed the creation of many breathtaking and inspiring works,” said Nigel Atherton, the Editor-in-Chief of Amateur Photographer. “Now, we are thrilled to see TECNO bringing professional-level snapshot capabilities to every smartphone user through the CAMON 40 Series, unlocking boundless creative potential. We look forward to seeing this year’s outstanding snapshot entries from around the world.”

Activate FlashSnap to Join a Global Snapshot Journey

Guided by the CAMON 40 Series’ “Perfect Snap Anytime” positioning, the Shot On CAMON Contest 2025 highlights signature FlashSnap Mode, celebrating fast-capture creativity and the power to freeze unforgettable moments in time. The three creative submission categories invite a diverse range of perspectives:

  • Snap Every Pulse: From natural wonders to urban dynamics, this theme invites participants to capture moments that reflect the rhythm of life—whether through dynamic scenes in nature, wildlife, street culture, or city energy.
  • Snap All Fleeting Bonds: Focus on the emotional depth of human connections. This theme welcomes submissions that reflect the warmth between family, friends, and pets.
  • Snap Any Motion: Capture dynamic movement—whether it is everyday actions or high-energy sports. Freeze the thrill of motion in your own visual language.

All entries must feature a visible TECNO watermark and be original content. Duplicate submissions will be disqualified. Complete contest rules and submission guidelines can be found by visiting the official TECNO website and social platforms.

Share Photographic Creativity to Win a London Trip & Amazing Cash Prizes

To enhance accessibility, TECNO has introduced a dedicated submission portal on its global official website, making it easy for users to turn fleeting moments into lasting visual stories. To enter, users should post their shots captured on the CAMON 40 on Instagram with #ShotOnCAMON and #TECNOCAMON40Series and submit high-resolution versions either via email at shotoncamon@tecno-mobile.com or directly through the online portal.

One outstanding photographer will be awarded the Grand Prize of $10,000 and the honorary title of “TECNO Photography Master” — the highest honor of the competition. Each of the three themes will be awarded a Gold Prize ($5,000), Silver Prize ($3,000), and Bronze Prize ($1,000)—resulting in a total of nine category winners. All winning participants stand a chance to join an exclusive Photography Tour in London.

Additionally, the TECNO Friend Prize will award ten CAMON 40 Premier 5G smartphones to the top IG Reels creators. Winning works will also be showcased in global media exhibitions, the TECNO annual photo book, and across TECNO’s official platforms.

To bring the Shot On CAMON spirit closer to users, TECNO will host offline snapshot challenges from June to August at flagship stores in key markets. CAMON 40 Series users will have the opportunity to experience fast-shooting firsthand, capture life’s best moments, and submit entries to the global Shot On CAMON contest. These events will highlight TECNO’s AI imaging capabilities while inspiring creative expression.

The CAMON 40 Series redefines mobile imaging with its innovative FlashSnap technology, helping every user to tell the story of their lives through captivating images. This user-centric approach has boosted the brand’s efforts to democratize premium imaging technologies throughout emerging markets, making TECNO a trusted partner to capture the magic moments of vibrant life.

For more details and contest rules, please visit shotoncamon.com or follow @tecnomobile on Instagram.

 

U.S. Immigration Fund Welcomes Kiem Nguyen as Vice President of Business Development, Head of Southeast Asia Market

PALM BEACH, Fla., May 1, 2025 /PRNewswire/ — U.S. Immigration Fund, a leading EB-5 Regional Center operator, is pleased to welcome Kiem Nguyen as Vice President of Business Development, Head of Southeast Asia Market. With over a decade of experience in the EB-5 investment industry, Kiem brings a deep understanding of investor needs and a strategic vision to further expand U.S. Immigration Fund’s presence in Southeast Asia.

Kiem Nguyen joins U.S. Immigration Fund as Vice President of Business Development, Head of Southeast Asia Market
Kiem Nguyen joins U.S. Immigration Fund as Vice President of Business Development, Head of Southeast Asia Market

Born and raised in Vietnam, Kiem moved to the United States as a teenager, where he pursued his education, earning a B.A. in Economics and an MBA in International Business. Having lived and worked in both corporate roles and with the U.S. government, he offers a unique perspective on the immigration and business landscapes in both regions. Over the years, he has successfully guided numerous investors through the EB-5 process, helping families relocate, establish businesses, and build their futures in the U.S.

Kiem’s extensive experience includes living in California, Florida, and North Carolina, giving him firsthand insight into the diverse economic and cultural environments that new immigrants encounter. His expertise allows him to provide valuable guidance to families looking to invest, live, work, and grow businesses in the U.S.

In his new role at U.S. Immigration Fund, Kiem will focus on strengthening relationships with investors and partners across Southeast Asia, ensuring they have access to top-tier EB-5 investment opportunities. He is committed to enhancing education and transparency around the EB-5 program, empowering investors with the knowledge and confidence to make informed decisions about their future.

“I am excited to join U.S. Immigration Fund and work with a team dedicated to excellence in the EB-5 industry,” said Kiem. “For many investors in Southeast Asia, EB-5 is not just about immigration—it’s about securing better opportunities and a brighter future for their children. I look forward to helping families make informed decisions and achieve their long-term goals.”

Ashley Flucas, Chief Strategy Officer & General Counsel of U.S. Immigration Fund, underscores the firm’s commitment to investor support: “Kiem Nguyen brings a wealth of experience and an extensive network in the Southeast Asian market, making him an invaluable addition to our team as Vice President of Business Development, Head of South East Asia. His expertise will allow us to further support investors in navigating the EB-5 program with confidence. We look forward to working alongside Kiem as we continue our mission of providing world-class service and opportunities for those seeking to invest in the United States.”

Since its founding, U.S. Immigration Fund has helped thousands of families navigate the EB-5 process, successfully funding large-scale real estate projects with billions in investment capital. With Kiem’s leadership, U.S. Immigration Fund will continue expanding its global reach, providing exceptional service and investment opportunities to families in Southeast Asia seeking U.S. residency.

For more information or to schedule a consultation with Kiem Nguyen, use the links below.

Book a Consultation with Kiem

Visit our website

 

A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis

SUZHOU, China, May 1, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)), has completed the first interim analysis and met the pre-specified primary endpoint of progression-free survival (PFS) as evaluated by an Independent Data Monitoring Committee (IDMC), with both statistical significance and clinical relevance.

KN026-001 is a randomized, multicenter, Phase II/III clinical study designed to evaluate the efficacy of KN026 in combination with chemotherapy inpatients with HER2-positive advanced, unresectable, or metastatic GC (including GEJ) who have failed first-line treatment. Part 2 of KN026-001 is a randomized, double-blind, placebo-controlled Phase III study. Patients with HER2-positive GC (including GEJ) who had previously received and failed at least first line standard treatment were enrolled and randomized 1: 1 to receive either KN026 in combination with chemotherapy or placebo in combination with chemotherapy. The primary endpoints of this study are PFS and overall survival (OS) as assessed by the Independent Review Committee (IRC).

The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.

About KN026

KN026 is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, leading to HER2 signal blockade. KN026 has demonstrated better tumor inhibition in HER2-positive tumor cell lines compared with trastuzumab and pertuzumab in combination. Additionally, KN026 has also shown inhibitory effect on tumor cells with trastuzumab-resistant cell lines.

The results of multiple clinical studies in different stages showed that KN026 has significant anti-tumor activities, even in heavily pretreated patients with HER2-positive breast cancer (BC) and gastric cancer (GC), including those with prior anti-HER2 treatment. Currently, several pivotal clinical trials of KN026 for the second-line and beyond treatment of HER2-positive GC/gastroesophageal junction cancer (GEJ), the first-line treatment of HER2-positive BC, neoadjuvant treatment for HER2-positive BC are being conducted. KN026 in combination with chemotherapy for the treatment of patients with HER2-positive GC (including GEJ) who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA).

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China, pursuant to which, JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a differentiated and globally competitive product portfolio, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs to benefit patients.

Canadian Solar Files Annual Report on Form 20-F for Year Ended December 31, 2024

KITCHENER, ON, May 1, 2025 /PRNewswire/ — Canadian Solar Inc. (the “Company”, or “Canadian Solar”) (NASDAQ: CSIQ), today announced the filing of its annual report on Form 20-F for the year ended on December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F can be accessed on the Company’s Investor Relations website at www.canadiansolar.com or on the SEC’s website at www.sec.gov.

About Canadian Solar

Canadian Solar is one of the world’s largest solar technology and renewable energy companies. Founded in 2001 and headquartered in Kitchener, Ontario, the Company is a leading manufacturer of solar photovoltaic modules; provider of solar energy and battery energy storage solutions; and developer, owner, and operator of utility-scale solar power and battery energy storage projects. Over the past 24 years, Canadian Solar has successfully delivered nearly 150 GW of premium-quality, solar photovoltaic modules to customers across the world. Through its subsidiary e-STORAGE, Canadian Solar has shipped over 10 GWh of battery energy storage solutions to global markets as of December 31, 2024, boasting a US$3.2 billion contracted backlog as of December 31, 2024. Since entering the project development business in 2010, Canadian Solar has developed, built, and connected approximately 11.5 GWp of solar power projects and 4.5 GWh of battery energy storage projects globally. Its geographically diversified project development pipeline includes 25 GWp of solar and 75 GWh of battery energy storage capacity in various stages of development. Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

Canadian Solar Inc. Investor Relations Contact

Wina Huang
Investor Relations
Canadian Solar Inc.
investor@canadiansolar.com 

U.S. Immigration Fund Welcomes Benny Chang as Director of Business Development, Taiwan

PALM BEACH, Fla., May 1, 2025 /PRNewswire/ — U.S. Immigration Fund (USIF), a leading EB-5 Regional Center operator, is pleased to welcome Huaiyang “Benny” Chang as Director of Business Development, Taiwan. With extensive experience in international finance, investment, and global asset allocation strategies, Chang is poised to strengthen USIF’s presence in the Taiwanese market and beyond.

Benny Chang joins U.S. Immigration Fund as Director of Business Development, Taiwan
Benny Chang joins U.S. Immigration Fund as Director of Business Development, Taiwan

Chang began his career managing investment projects at a family office in Singapore, where he developed deep expertise in finance and investment. Since 2018, he has specialized in immigration and overseas real estate investment, advising investors on strategic asset allocation to achieve their financial and residency goals. His profound understanding of investor needs and the Taiwanese market makes him an invaluable addition to USIF’s global business development team.

“I am honored to join USIF, a globally recognized leader in the EB-5 industry,” said Chang. “I look forward to working alongside a world-class team to expand USIF’s reach and provide investors with premier EB-5 opportunities. Collaboration and trust are essential in this industry, and I am eager to build strong relationships with investors and partners worldwide.”

“We are pleased to have Benny Chang join our team,” says Ashley Flucas, Chief Strategy Officer & General Counsel of U.S. Immigration Fund. “His expertise in international investment and deep understanding of the Taiwanese market will help us better serve investors seeking U.S. residency. Benny’s appointment reflects our commitment to expanding USIF’s reach and ensuring our investors have access to the best opportunities available.”

Since its founding, USIF has helped thousands of families secure U.S. residency through EB-5 investments, successfully funding large-scale real estate projects with billions in capital. With Chang’s expertise in business development and investor relations, USIF aims to enhance its service offerings and expand its presence in Taiwan and other key global markets.

For more information or to schedule a consultation with Benny Chang, use the links below.

Book a Consultation with Benny

Visit our website

 

LG Display Becomes World’s First to Verify Commercialization of Blue Phosphorescent OLED Panels

Final Step to Achieving “Dream OLED”

SEOUL, South Korea, May 1, 2025 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced today that it has become the world’s first company to successfully verify the commercialization-level performance of blue phosphorescent OLED panels on a mass production line. The achievement comes about eight months after the company partnered with UDC to develop blue phosphorescence, and is considered a significant step closer to realizing a “dream OLED” display.

LG Display Becomes World's First to Verify Commercialization of Blue Phosphorescent OLED Panels
LG Display Becomes World’s First to Verify Commercialization of Blue Phosphorescent OLED Panels

In the display industry, “dream OLED” refers to an OLED panel that achieves phosphorescence for all three primary colors of light (red, green, and blue). OLED panel light emission methods are broadly categorized into fluorescence and phosphorescence. Fluorescence is a simpler process in which materials emit light immediately upon receiving electrical energy, but its luminous efficiency is only 25%. In contrast, phosphorescence briefly stores received electrical energy before emitting light. Although it is technically more complex, this method offers luminous efficiency of 100% and uses a quarter as much power as fluorescence.

However, achieving blue phosphorescence has remained a major challenge even more than 20 years after the commercialization of red and green phosphorescence. This is due to blue, among the three primary colors, having the shortest wavelength and demanding the greatest energy.

LG Display has solved this issue by using a hybrid two-stack Tandem OLED structure, with blue fluorescence in the lower stack and blue phosphorescence in the upper stack. By combining the stability of fluorescence with the lower power consumption of phosphorescence, it consumes about 15% less power while maintaining a similar level of stability to existing OLED panels.

In particular, LG Display is the first to succeed in reaching the commercialization stage of blue phosphorescent OLED panels, where performance evaluation, optical characteristics, and processability on actual mass production lines should all be confirmed. The company has already completed commercialization verification with UDC.

LG Display has independently filed patents for its hybrid blue phosphorescent OLED technology in both South Korea and the United States.

The company will showcase a blue phosphorescent OLED panel featuring two-stack Tandem technology at SID Display Week 2025, the world’s largest display event, in San Jose, California from May 11th (local time).

At the show, LG Display will be unveiling a blue phosphorescent OLED panel featuring two-stack Tandem technology applied to a small and medium-sized panel that can be applied to IT devices such as smartphones and tablets. As more and more products require high definition and high efficiency such as AI PCs and AR/VR devices, the application of blue phosphorescence technology is expected to expand rapidly.

“The successful commercialization of blue phosphorescence technology, which has been called the final piece of the ‘dream OLED’ puzzle, will become an innovative milestone towards the next generation of OLED,” said Soo-young Yoon, CTO and Executive Vice President of LG Display. “We expect to secure a leading position in the future display market through blue phosphorescence technology.”

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Manager, Communication Team
Email: hjy05@lgdisplay.com

Preserving fertility and optimising care for the one in seven women suffering from endometriosis

SINGAPORE, May 1, 2025 /PRNewswire/ — Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help preserve the fertility of those with the debilitating condition.

They have finalised a rigorous consensus process to create a defined and auditable standard for networks of expertise for endometriosis treatment for the one in seven females of reproductive age living with the chronic pelvic pain and fertility risk from the disease.

It sets a gold standard of patient-centred care for sufferers of endometriosis and a similar condition called adenomyosis while considering the diversity of countries, economies, cultures and societies in the APAC region.

The experiences and views of patients living with endometriosis and adenomyosis have been incorporated in developing the consensus structure.

Endometriosis occurs when tissue similar to the inner lining of the uterus grows outside the uterus. It often affects the ovaries, fallopian tubes and the tissue lining the pelvis. Currently, there is no absolute preventive strategy or cure for the condition, but treatment options can help manage its chronic impacts.

The new approaches to endometriosis treatment will be outlined this week at the 2025 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Singapore.

The Congress from today (1 May) to Sunday has brought together over 2,000 scientists, clinicians, nurses and counsellors for a program that will help shape the future of fertility health care in the region and around the world.

New Zealand fertility specialist Professor Neil Johnson, an ASPIRE Board member and Past President of the World Endometriosis Society, has led the endometriosis consensus program with international specialists in the field.

“The topics covered and the way that they have been addressed set new world standards in care, and our hope is that they will influence policy makers and those responsible for health funding decisions,” Professor Johnson explained. 

“My aspiration for the networks of expertise consensus is that it presents what our APAC experts believe to be the optimal model of how complex multidisciplinary care in endometriosis should be best structured. 

“Currently, there is a wide variation in the quality of multidisciplinary care for endometriosis. In many settings, care is provided without the key structures and enmeshment that is crucial for coordinated patient care. 

“This consensus has the potential to become an accreditation gold standard.  It may then be possible to assess the calibre of endometriosis care services across APAC to determine whether they meet the ASPIRE standard to be defined as a network of expertise.

“The consensus on fertility preservation in endometriosis is an issue that has come into sharp focus. In the past, repeated ovarian surgery for endometriosis sufferers has meant that some patients have ended up with extremely low ovarian reserve, which refers to the quantity of eggs remaining in the ovaries with egg quality often negatively affected by endometriosis.

“In some cases, ovarian reserve has become so low that it is very difficult for these patients to achieve a pregnancy either through natural conception or medically assisted reproduction. This is a tragic outcome for young women.

“Our consensus emphasises the need for awareness that endometriosis itself can compromise ovarian reserve along with the impact of ovarian surgery. 

“It highlights the importance of blood testing for anti-mullerian hormone (AMH) levels and ovarian ultrasound for antral follicle count to accurately measure a patient’s ovarian reserve.

“Timing of pregnancy is another important consideration. While it is a personal choice, the ability to conceive may be affected by a decision to delay attempts to become pregnant.

“Of prime importance is the provision of information on fertility preservation to endometriosis sufferers no later than in their twenties. This is vital for patients with severe (stage IV) endometriosis or those facing ovarian surgery. 

“Fertility preservation is typically through egg freezing, although embryo freezing might be preferred by some couples in committed relationships.

“Ovarian tissue freezing may be considered in exceptional cases for endometriosis. Typically, this is an option for cancer patients facing potentially sterilising chemotherapy in the oncology setting. However, more research is needed to explore the role of ovarian tissue freezing for those with endometriosis.   

“Finally, our consensus teams highlight the importance of integrating psychological support and overall fertility counselling as a critical aspect of care.

The ASPIRE 2025 Congress is being held at the Suntec Convention and Exhibition Centre in Singapore. For further information, go to www.ASPIRE2025.com

INTERVIEW: Professor Neil Johnson is available for interview.
To arrange, please contact Trevor Gill, ASPIRE Congress Media Relations
Telephone +61 418 821948 or email lighthousepr@adelaide.on.net